Axsome Therapeutics Stock Cash Flow From Operations
| AXSM Stock | USD 118.23 2.13 1.77% |
Axsome Therapeutics fundamentals help investors to digest information that contributes to Axsome Therapeutics' financial success or failures. It also enables traders to predict the movement of Axsome Stock. The fundamental analysis module provides a way to measure Axsome Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Axsome Therapeutics stock.
Axsome | Cash Flow From Operations |
Axsome Therapeutics Company Cash Flow From Operations Analysis
Axsome Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Axsome Therapeutics Cash Flow From Operations | (128.41 M) |
Most of Axsome Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axsome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Axsome Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Axsome Therapeutics is extremely important. It helps to project a fair market value of Axsome Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Axsome Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Axsome Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Axsome Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Axsome Therapeutics has (128.41 Million) in Cash Flow From Operations. This is 124.35% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 113.22% higher than that of the company.
Axsome Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axsome Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics of similar companies.Axsome Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Axsome Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Axsome Therapeutics from analyzing Axsome Therapeutics' financial statements. These drivers represent accounts that assess Axsome Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Axsome Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 3.0B | 1.4B | 3.1B | 3.6B | 4.1B | 4.3B | |
| Enterprise Value | 2.9B | 1.4B | 3.0B | 3.4B | 3.9B | 4.1B |
Axsome Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Axsome Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Axsome Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Axsome Fundamentals
| Return On Equity | -2.32 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.74) % | ||||
| Operating Margin | (0.52) % | ||||
| Current Valuation | 5.75 B | ||||
| Shares Outstanding | 48.77 M | ||||
| Shares Owned By Insiders | 16.59 % | ||||
| Shares Owned By Institutions | 77.48 % | ||||
| Number Of Shares Shorted | 5.87 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 102.94 X | ||||
| Price To Sales | 16.33 X | ||||
| Revenue | 385.69 M | ||||
| Gross Profit | 352.39 M | ||||
| EBITDA | (280.56 M) | ||||
| Net Income | (287.22 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 191.53 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 1.17 X | ||||
| Cash Flow From Operations | (128.41 M) | ||||
| Short Ratio | 5.02 X | ||||
| Earnings Per Share | (5.99) X | ||||
| Target Price | 173.0 | ||||
| Number Of Employees | 683 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 6.3 B | ||||
| Total Asset | 568.5 M | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 254.96 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 568.5 M |
About Axsome Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axsome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Axsome Therapeutics Piotroski F Score and Axsome Therapeutics Altman Z Score analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.99) | Revenue Per Share | Quarterly Revenue Growth 0.66 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.